Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures

  title={Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures},
  author={Orrin Devinsky and R. Faught and B. Joe Wilder and Andres M. Kanner and Marc Kamin and Lynn D. Kramer and A. Rosenberg},
  journal={Epilepsy Research},
The efficacy and safety of felbamate monotherapy were evaluated in 52 patients with refractory partial seizures with or without secondary generalization in a double-blind, randomized, placebo-controlled trial. Each patient completed a routine evaluation for epilepsy surgery and was randomized to receive either felbamate, titrated to a maximum daily dose of 3600 mg over 2 days, or placebo during the 10-day, inpatient, treatment phase. An intent-to-treat analysis was performed on the data of all… Expand
Felbamate in therapy-resistant epilepsy: an Italian experience
The results of this uncontrolled study suggest that felbamate could be useful in patients with epilepsies which are refractory to other antiepileptic drugs after careful risk-benefit assessment and consideration of all circumstances involved. Expand
Felbamate in refractory partial epilepsy
Even if the patients sample is small FBM proves its efficacy in partial epilepsy, showing a relatively well tolerated profile. Expand
Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures.
Results demonstrate that oxcarbazepine given as monotherapy is effective and safe for the treatment of partial seizures in this paradigm. Expand
Efficacy of felbamate in the treatment of intractable pediatric epilepsy.
Evidence is added that felbamate is an important antiepileptic drug for medically refractory epilepsy in children and is well tolerated with few adverse effects, as evaluated in a pediatric population with intractable epilepsy. Expand
Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures
This trial demonstrated that OXC at 2400 mg/day is well tolerated and efficacious when administered as monotherapy in patients with uncontrolled partial onset seizures. Expand
Oxcarbazepine monotherapy for partial-onset seizures
OXC is safe and effective in the treatment of patients with partial epilepsy previously receiving treatment with other antiepileptic drugs, and the results of this trial are consistent with previous monotherapy trials with OXC. Expand
Felbamate as an add-on therapy for refractory epilepsy.
No reliable evidence is found to support the use of felbamate as an add-on therapy in patients with refractory partial-onset epilepsy, and a large scale, randomized controlled trial conducted over a greater period of time is required to inform clinical practice. Expand
Gabapentin monotherapy: I. An 8-day, double-blind, dose controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures
It is demonstrated that gabapentin has anticonvulsant activity and is well tolerated when administered as monotherapy in patients with refractory partial seizures in patients whose antiepileptic medications had been discontinued for seizure monitoring. Expand
Monotherapy trials: presurgical studies
Presurgical inpatients studies have been carried out using felbamate, gabapentin and oxcarbazepine to elucidate AED activity and show statistically significant differences between active and control treatments during short-term therapy, and are therefore of use in fulfilling regulatory requirements. Expand
Practice Advisory: The Use of Felbamate in the Treatment of Patients with Intractable Epilepsy
In 1993, felbamate (FBM) was approved by the Food and Drug Administration and represented a significant advance for many patients with inadequately controlled seizures or with significant side effects for whom no options had been available. Expand


Felbamate: A double‐blind controlled trial in patients undergoing presurgical evaluation of partial seizures
The ability of felbamate to quickly and safely reduce the occurrence of frequent partial-onset seizures and maintain effective seizure control following reductions in the dosages of standard antiepileptic drugs is demonstrated. Expand
Felbamate monotherapy: Controlled trial in patients with partial onset seizures
FBM monotherapy was effective in the treatment of partial onset seizures with or without generalization and demonstrated a favorable safety profile. Expand
Felbamate monotherapy for partial‐onset seizures
FBM monotherapy was effective in the treatment of partial-onset seizures with or without secondarily generalized seizures and demonstrated a favorable safety profile. Expand
Clinical Trials of Investigational Antiepileptic Drugs: Monotherapy Designs
Two trial designs are described: a placebo‐ control design with inpatients who in undergoing a presurgery seizure evaluation have had all antiepileptic drugs discontinued; and an active‐control design aimed at showing the test drug superior to the control treatment, thus avoiding the interpretational difficulties of no‐difference outcomes. Expand
The natural history of drug resistant epilepsy: epidemiologic considerations.
Predictors of poor outcome are not necessarily the converse of predictors of good outcome, but identification of such factors is important to allow earlier referral of patients destined to meet criteria for intractable to allow alternative therapies to be instituted. Expand
Surgical Treatment of Epilepsy
A seizure- free patient should be the goal of both medical and surgical therapy, and the outcomes of both should be presented so that the proportion of patients totally seizure-free (and not just with major improvement) can be determined. Expand
Controlled Clinical Trials in Neurological Disease
This work designs and implementation and Interpretations of Controlled Clinical Trials for Epilepsy and applications to Diseases of the Nervous System, and examines the role of perspective in the design and interpretation of these trials. Expand
The role of radiation therapy following resection of single brain metastasis from melanoma
It is concluded that patients with single brain metastasis from melanoma have improved control of CNS disease when postoperative RT is administered, and survival depends upon control of systemic disease. Expand
Perspective of the Food and Drug Administration
This chapter is primarily concerned with describing the perspective of the Food and Drug Administration about what constitutes appropriate controlled trials of drugs in patients with epilepsy and it is important to describe in some detail the relevant law and regulations that the Agency is charged with enforcing. Expand